




ClearXview

An AI-powered Orthopaedic Diagnostic Imaging Solution

Background (UK Scale)



Background (Individual Patient)



4-6 MONTHS

 **Imaging Referral
Waiting Time**



£107 Per Month


 **Repetitive Procedures**

Background

“95% of the diagnosis rely on 2D X-rays interpreted by clinicians without specialised training—especially during early-stage screening.”



Treatment process



Knee Osteoarthritis symptoms dismissed as normal ageing

Ageing is the leading risk factor for KOA. The prevalence increases significantly in individuals over 40.



GP: Lack of professionals/ diagnostic tools

Imaging is only referred when multi-morbidity were suspected.



X-rays: The primary screening tool

Its 2D nature lacks of sufficient details and contrast for capturing early joint changes.

Problem

No Early And Accurate Diagnosis



41%

**Miss diagnosed in
Radiology**

NICE NG226 advise against
routine imaging for KOA-
only diagnosis



£ 2.53B

NHS annual spending

on KOA management,
including prescriptions and
all kinds of non-invasive
treatments.




1 Year


**delayed diagnosis for
half of patients**

23 interviewed patients feel
they must 'self-learn' how to
describe symptoms to
trigger a referral

Solution



Class I Medical Software




**Cross validated on:
Unique, Global-scale Dataset**


>10,000 Imperial NHS Trust, UK military (ADVANCED), US (NMDID, cadaver), EU (TotalSegmentator), East Asian (KD)
Dataset



Class I Medical Software



Class I Medical Software



Class I Medical Software

400
Million

* Repetitive imaging referrals of UK KOA population

Unnecessary Referrals

< 1 Day

ClearXview

ClearXview

Class I Medical Software

Benefits

Cost savings for the NHS, improved decision-making for healthcare providers, and better outcomes for KOA patients.



Healthcare System

- **Cost-saving (UK alone)**
£269M reduction on imaging assessments
£163.5M reduction on unnecessary surgery



Healthcare Providers

- **Reduce uncertainty**
- **Efficiency in reporting**



Knee Osteoarthritis Patients

- **Reduce disability**
- **Reduce social care costs**

Revenue Model (B2B)



Standard

Include

- PACS integration

£120,000
per trust



Premium

Everything from Standard plus

- Personalised surgical plan

£150,000
per trust



Enterprise

Include

- Enterprise-grade identity

request for quote

* 215 Trust in the UK

Market Opportunity

TAM

Diagnostic Imaging¹

\$ 50.1B

SAM

Diagnostic X-ray imaging for orthopedics²

\$ 13.7B

SOM


Diagnostic Imaging for Knee Osteoarthritis

\$ 1.7B

- 1. Precedence Statistics
- 2. Global Market Insights

Competition

Our advantage in 3D AI analysis



Traction

Non-dilutive Fund

15+ years of research
£millions in grant
£40k to kick-start



01



People Engagement

02

150+ Global radiologists &
orthopedic surgeons
20+ MSK patients



Imperial College
Healthcare
NHS Trust



EUROPEAN SOCIETY
OF RADIOLOGY

Partner Engagement

cadaver validation in Nov 2024

LOI obtained



04

03

Technical Validation

97% reconstruction accuracy



Team

Expert leaders from Imperial and NHS, advancing the future of diagnostic AI in orthopaedics.

IMPERIAL

IMPERIAL

IMPERIAL

NHS

IMPERIAL



Dr Renyong Gu
CEO & Founder

AI expert in medical
imaging

10+ years in translational
research



Prof Anthony MJ Bull
Co-founder

Musculoskeletal
biomechanics expert

Cofounded 4 startups



Dr Wenjia Bai
AI Scientist

Tech Consultant

MICCAI Area Chair, IEEE
Editorial Board



Dr Gareth Jones
Consultant Surgeon

Orthopedic expert

21 years in knee
biomechanics & osteoarthritis



Dr Shuqiao Xie
Chief Operational Officer

RAEng Enterprise Fellow


Experienced Start-up Co-
founder

The Ask

£ 100,000

Clinical Validation | 45%

- Software testing (IEC62304)
- UK pilot study
- clinical feedback
- patient group engagement
- Usability engineering test
- Design history file




50% | Staff & Consultancy

- Legal services
- Tech optimisation
- Commercial efforts
- Regulatory manager

5% | Partnership

- distribution channel
- multi-centre testing

Roadmap





Fast, Accurate, Accessible

Invest with us

clearxview.com